- Visibility 258 Views
- Downloads 246 Downloads
- Permissions
- DOI 10.18231/j.ijceo.v.11.i.3.30
-
CrossMark
Effect of topical nepafenac versus fluorometholone on macular thickness after Nd:YAG capsulotomy
- Author Details:
-
Rimmi Jha
-
Ashish Chander
-
Priye Suman Rastogi
-
Bhavika Adlakha
Rimmi Jha
Ashish Chander
Priye Suman Rastogi
Bhavika Adlakha
Background: The most common complication following an uncomplicated cataract surgery is Posterior capsular opacification (PCO). Nd:YAG (Neodymium yttrium aluminium garnet) capsulotomy is a safe, non-invasive OPD based procedure to manage an intact PCO. Transient increase in macular thickness have been an observed phenomenon following Nd:YAG capsulotomy. This study aimed to establish standard guidelines for medications to be prescribed after Nd:YAG capsulotomy to mitigate complication of increase in macular thickness & inflammation by analysing the effect of topical Nepafenac versus Fluorometholone.
Materials and Methods: A total of 96 patients diagnosed with PCO in Ophthalmology OPD of TMMC & RC, Moradabad, Uttar Pradesh, were enrolled for Nd:YAG capsulotomy over a period of one year. Optical coherence tomography was done pre and post laser to note macular thickness. Patients were randomised into group A & B and were prescribed topical Nepafenac and Fluorometholone respectively. Follow up was done after an hour, 1 week, 4 weeks, and 12 weeks and the effect of the two drugs on macular thickness was compared. Appropriate statistical tests were applied for data analysis.
Results: Total energy used during capsulotomy was in the range of 12 to 33 mJ in both the groups. The mean macular thickness at baseline was 242.7 ± 18.5 μm pre laser, which significantly increased to 268.9 ± 26.1 μm after 1 hour of treatment showing statistically significant increase compared to baseline. This gradually reduced to 259.1 ± 20.6 μm by week 12 indicating an acute increase in macular thickness after Nd:YAG capsulotomy in both the groups. There were weak to moderate correlations between total energy utilised and changes in Macular thickness. The results indicated that after Nd:YAG capsulotomy, medication is recommended, with both topical NSAIDs and topical steroids being effective options. However, topical NSAIDs may be preferred in cases where the use of steroids poses potential risks.
Conclusion: Both Nepafenac and Fluorometholone eye drops demonstrated comparable effects on acute increase in macular thickness in patients of PCO who were managed with Nd:YAG posterior capsulotomy.
References
- Karahan, E.; Er, D.; Kaynak, S. An Overview of Nd:YAG Laser Capsulotomy. Med Hypothesis Discov Innov Ophthalmol 2014, 3 (2), 45–50.
- Menon GJ, Wong KK, Bundhun T, Ewings P, Twomey JM. The effect of Nd:YAG laser posterior capsulotomy on stereoacuity. Eye (Lond). 2009;23(1):186–9.
- Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification: a problem reduced but not yet eradicated. Arch Ophthalmol. 2009;127(4):555–62.
- Soubrane, G. Macular Edema of Choroidal Origin. Dev Ophthalmol. 2017;58:202–19.
- Chun AG. Comparison of incidence of cystoid macular edema following Nd:YAG capsulotomy in postoperative treatment with topical steroids versus non-steroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci. 2011;52(14):4516.
- Cho H, Madu A. Etiology and treatment of the inflammatory causes of cystoid macular edema. J Inflamm Res. 2009;2:37–43.
- Pandya BU, Grinton M, Mandelcorn ED, Felfeli T. Retinal optical coherence tomography imaging biomarkers: a review of the literature. Retina. 2024;44(3):369–80.
- Wielders LHP, Schouten JSAG, Winkens B, van den Biggelaar FJHM, Veldhuizen CA, Findl O, et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018;44(4):429–39.
- Atilgan CU, Kosekahya P, Yetkin E, Caglayan M, Goker YS, Sendul SY. Effects of topical nepafenac and fluorometholone on macular thickness after posterior capsulotomy using neodymium-doped yttrium-aluminum-garnet laser. Beyoglu Eye J. 2020;5(2):64–72.
- Karahan E, Tuncer I, Zengin MO. The effect of ND:YAG laser posterior capsulotomy size on refraction, intraocular pressure, and macular thickness. J Ophthalmol. 2014:846385.
- Meacock W, Spalton D, Stanford M. Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol. 2000;84(3):332–6.
- Aslam TM, Devlin H, Dhillon B. Use of Nd:YAG laser capsulotomy. Surv Ophthalmol. 2003;48(6):594–612.
- Murrill CA, Stanfield DL, Van Brocklin MD. Capsulotomy. Optom Clin. 1995;4(4):69–83.
- Cetinkaya S, Cetinkaya YF, Yener HI, Dadaci Z, Ozcimen M, Oncel Acir N. The influence of size and shape of Nd:YAG capsulotomy on visual acuity and refraction. Arq Bras Oftalmol. 2015;78(4):220–3.
- Auffarth GU, Nimsgern C, Tetz MR, Völcker HE. [Analysis of energy levels for Nd:YAG laser capsulotomy in secondary cataract]. [Article in German]. Ophthalmologe. 2000;97(1):1–4. Jha et al. / Indian Journal of Clinical and Experimental Ophthalmology 2025;11(3):551–557 557
- Bhargava R, Kumar P, Phogat H, Chaudhary KP. Neodymium- yttrium aluminium garnet laser capsulotomy energy levels for posterior capsule opacification. J Ophthalmic Vis Res. 2015;10(1):37–42.
- Ari S, Cingü AK, Sahin A, Çinar Y, Çaça I. The effects of Nd:YAG laser posterior capsulotomy on macular thickness, intraocular pressure, and visual acuity. Ophthalmic Surg Lasers Imaging. 2012;43(5):395–400.
- Channell MM, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1984;102(7):1024–6.
- Richter CU, Arzeno G, Pappas HR, Steinert RF, Puliafito C, Epstein DL. Intraocular pressure elevation following Nd:YAG laser posterior capsulotomy. Ophthalmology. 1985;92(5):636–40.
- Miyake K, Ota I, Miyake G, Numaga J. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. J Cataract Refract Surg. 2011;37(9):1581–8.
- Jinagal J, Sahu S, Gupta G, Khurana S, Gupta R, Chawla Gupta P, et al. Quantification of inflammation following Nd:YAG laser capsulotomy and assessing the anti-inflammatory effects of nepafenac 0.1% and betamethasone 0.1. Ocul Immunol Inflamm. 2021;29(2):411–6.
- Hoffman RS, Braga-Mele R, Donaldson K, Emerick G, Henderson B, Kahook M, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2016;42(9):1368–